Looking for funding? Subscribe to news
close icon
Shape

PredictImmune

Developer of pioneering prognostic tools

Company bio

Founded in May 2017 and based at the Babraham Research Campus in Cambridge, PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn’s and ulcerative colitis (IBD).

Based on ten years of research at Cambridge University, PredictImmune’s test kits help both clinicians and patients to understand, at the point of diagnosis, the likely course of disease and opens the possibility of better treatment choices from the outset.

Company
information

Head office

Cambridge

 

CEO

Paul Kinnon

 

Chair

Andrew P Sandham

 

Website

predictimmune.com

BGF office

London

 

BGF team

Tim Rea

Nathan Heath

 

Invested since

July 2019

 

Total BGF investment

£4m